Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
drotaverine + mefenamic acid (Resilient Cosmeceuticals Pvt. Ltd.)
- Development stage
- Unknown
- Lead developer
- Resilient Cosmeceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Termispaz-MF is a fixed-dose combination tablet containing the antispasmodic agent drotaverine and the non-steroidal anti-inflammatory drug (NSAID) mefenamic acid. Developed by Resilient Cosmeceuticals, it is approved for the management of spasmodic dysmenorrhea, menorrhagia, abdominal pain, and pain associated with intrauterine device (IUD) insertion. Drotaverine acts as a selective inhibitor of phosphodiesterase-4 (PDE4), leading to increased intracellular cyclic AMP levels and subsequent smooth muscle relaxation without significant anticholinergic side effects. Mefenamic acid provides analgesic and anti-inflammatory activity by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins that mediate pain and uterine contractions.
- Brand names
- Termispaz-MF
- Other names
- drotaverine hydrochloride + mefenamic acid
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)LTCC (Voltage-gated calcium channel (L-type))PDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on drotaverine + mefenamic acid (Resilient Cosmeceuticals Pvt. Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on drotaverine + mefenamic acid (Resilient Cosmeceuticals Pvt. Ltd.).